Legitimate use of Controlled Drugs, for example for R&D activities, is enabled in the UK through scheduling under the Misuse of Drugs Regulations 2001, which regulates their availability according to their medicinal value and perceived risk of misuse.
In the Misuse of Drugs Act 1971, compounds can be controlled either by (i) name or (ii) a description of a core chemical structure and a range of modifications (generic controls), which provides broad coverage to cover multiple chemicals. Generic controls have been developed and previously recommended by the Advisory Council on Misuse of Drugs (ACMD), who advise the Home Office, to capture groups of compounds that are closely related in structure to known drugs of abuse. ACMD has made recommendations to reduce barriers to research, using compounds described by the third generation synthetic cannabinoid receptor agonists generic definition.
This webinar will cover the background and how the Pistoia Alliance Controlled Substance Compliance and Shipping (CSCS) expert community investigates the potential implications of such proposals.

  • Ian Johns, Director Scitegrity
  • Zofia Jordan, Consultant


Fill in the form below to access a link to the recording